SynCardia Total Artificial Heart (STAH) system
Syncardia Systems, LLC · Decision date Dec 17, 2025
What did the FDA approve?
FDA records P030011/S096 as a supplement to PMA P030011, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 17, 2025.
FDA approval order statement
Approval for alternate battery pack cells and cell separator used in the Freedom Driver.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 17, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P030011/S096
- Regulatory pathway
- PMA supplement
- Applicant
- Syncardia Systems, LLC
- Product code
- LOZ
- Decision code
- APPR
- Decision date
- Dec 17, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Artificial heart.
- Applicant
- Syncardia Systems, LLC
- Product code
- LOZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P030011/S096 received
Application receipt date recorded by FDA.
P030011/S093 · Related supplement
Total Artificial Heart
P030011/S096 · FDA decision
Real-Time Process
P030011/S097 · Related supplement
SynCardia Total Artificial Heart (STAH) System
P030011/S099 · Related supplement
SynCardia Temporary Total Artificial Heart (TAH-t) System Freedom Driver System
Timeline entries are records held by MedtechLedger for P030011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Total Artificial HeartP030011/S093 | Syncardia Systems, LLC | PMA supplement | Nov 19, 2025 | FDA |
SynCardia Total Artificial Heart (STAH) SystemP030011/S097 | Syncardia Systems, LLC | PMA supplement | Feb 20, 2026 | FDA |
| Syncardia Systems, LLC | PMA supplement | Jul 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Syncardia Systems, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1992 E. Silverlake Rd., Tucson, AZ, 85713
Sources and methodology
- Original FDA record: P030011/S096
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

